Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:30:04 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Z:BHVN - BIOHAVEN LTD - http://biohavenpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BHVN - Z0.538.00·39.690.138.99-3.17-7.53,353.1129,61619,92242.36  43.235  37.6162.21  12.3519:54:30Apr 1815 min RT 2¢

Recent Trades - Last 10 of 19922
Time ETExPriceChangeVolume
19:54:30Z38.99-3.1710
16:57:00Z39.00-3.161
16:56:23Z39.00-3.161
16:24:41Z38.99-3.171
16:15:14Z39.79-2.375
16:05:20Z38.989-3.17110,495
16:05:20Z38.989-3.17153,630
16:05:00Z38.99-3.1764,125
16:04:47Z38.99-3.1776
16:04:24Z38.99-3.17156

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 06:00U:BHVNNews ReleaseBiohaven Announces Pricing of $230 Million Public Offering of Common Shares
2024-04-17 16:05U:BHVNNews ReleaseBiohaven Announces Proposed Public Offering of Common Shares
2024-04-13 09:00U:BHVNNews ReleaseBiohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
2024-02-29 16:05U:BHVNNews ReleaseBiohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
2024-01-08 07:30U:BHVNNews ReleaseBiohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncol
2024-01-02 07:00U:BHVNNews ReleaseBiohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 16:30U:BHVNNews ReleaseBiohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
2023-11-14 16:05U:BHVNNews ReleaseBiohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
2023-10-16 07:00U:BHVNNews ReleaseBiohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek ‚ ®
2023-10-05 16:05U:BHVNNews ReleaseBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2023-10-02 23:56U:BHVNNews ReleaseBiohaven Announces Pricing of $225 Million Public Offering of Common Shares
2023-10-02 16:36U:BHVNNews ReleaseBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
2023-09-14 07:00U:BHVNNews ReleaseBiohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
2023-09-05 07:00U:BHVNNews ReleaseBiohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
2023-07-31 09:31U:BHVNNews ReleaseBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
2023-07-31 06:59U:BHVNNews ReleaseBiohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
2023-07-27 07:00U:BHVNNews ReleaseBiohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
2023-05-31 07:00U:BHVNNews ReleaseBiohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
2023-05-25 17:00U:BHVNNews ReleaseBiohaven to Present R&D Day at Yale School of Management
2023-05-12 16:30U:BHVNNews ReleaseBiohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments